- Tumors1000+
- Pathologic Processes1000+
- Pathology1000+
- Cancer850
- Nervous System Diseases760
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes1000+
- Pathology1000+
- Cancer850
- Nervous System Diseases760
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PR positive
- EGFR negative
- PD-L1 negative
- EGFR positive
- ER negative
- ALK negative
- PR negative
- KRAS positive
- BRAF positive
- CD20 positive
- BRCA1 positive
- BRCA2 positive
- p16 positive
- ALK positive
- BRAF negative
- MET positive
- ROS1 negative
- p16 negative
- HLA positive
- HR positive
- MYC positive
- PIK3CA positive
- CD19 positive
- CD5 positive
- RET positive
- HLA-A positive
- IDH positive
- MET negative
- ROS1 positive
- BCL2 positive
- IDH negative
- dMMR positive
- BCL6 positive
- Ex19del positive
- L858R positive
- NRAS positive
- PALB2 positive
- TP53 negative
- TP53 positive
- BCR-ABL1 positive
- BRCA positive
- CCND1 positive
- HBsAg positive
- HLA negative
- HPV negative
- RET negative
- SMN1 positive
- BRCA1 negative
- CD4 positive
- CFTR positive
- FLT3 negative
- HLA-A negative
- HPV positive
- MSI-H positive
- RAS negative
- RAS positive
- TTR positive
- anti-dsDNA positive
- ABCA4 positive
- ANA positive
- BRCA2 negative
- CD20 negative
- CD23 positive
- CLDN18.2 positive
- EBV positive
- FGFR2 positive
- FLT3 positive
- KRAS negative
- MDM2 positive
- MSS positive
- NTRK negative
- NTRK positive
- PTEN positive
- Philadelphia chromosome negative
- Philadelphia chromosome positive
- RB1 negative
- RB1 positive
- SMN2 positive
- T790M positive
- TROP2 negative
- TROP2 positive
- ctDNA positive
- t(11;14) positive
- 1p negative
- APP positive
- C5 positive
- CD19 negative
- COL7A1 positive
- FMR1 positive
- HRAS positive
- MGMT negative
- MLH1 positive
- MMR positive
- MSH2 positive
- MSH6 positive
- NF1 positive
- NF2 positive
- PMS2 positive
- PSEN1 positive
- PSEN2 positive
- RF positive
- RHO positive
- SPINK5 positive
- hepatitis B DNA negative
- pMMR positive
- β-thalassemia positive
- 11q negative
- 11q positive
- 19q negative
- AKT negative
- ALPL positive
- ATM positive
- Anti-Smith positive
- Aβ1-42 positive
- CD123 positive
- CD1a positive
- CD2 positive
- CD22 negative
- CD3 positive
- CD34 positive
- CD7 positive
- CD8 positive
- CD99 positive
- CDK4 positive
- COL1A1 positive
- COL1A2 positive
- DLL3 positive
- DMD positive
- Del(17p) negative
- EPCAM positive
- ER/PR positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GBA positive
- GLA positive
- GRN positive
- HBB positive
- HBV DNA negative
- HBsAg negative
- HEXA positive
- HEXB positive
- HPV16 positive
- HRD positive
- HbE positive
- HbSS positive
- IDS positive
- IGHV negative
- IGHV positive
- JAK2 positive
- KIT positive
- L861Q positive
- MGMT positive
- MMR negative
- MSI-H negative
- MYC negative
- NRAS negative
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PTCH1 positive
- PTEN negative
- PiZZ positive
- RAF positive
- S768I positive
- SMARCB1 negative
- SMARCB1 positive
- TTR negative
- TdT positive
- anti-AChR positive
- anti-MuSK positive
- anti-PLA2R positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- core antibody positive
- dMMR negative
- kappa light chain positive
- lambda light chain positive
- myeloperoxidase negative
- other sickle cell syndrome variants positive
- p53 positive
- surface antigen positive
- t(11;14) negative
- (null)(null) positive
- 11q del negative
- 11q del positive
- 11q23 abnormalities positive
- 12 negative
- 12 positive
- 13q del negative
- 13q negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Abrocitinib
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Active Treatment for Cutaneous Squamous Cell Carcinoma
- Active Treatment for Non-Invasive Basal Cell Carcinoma
- Adjuvant Radiation for 4-6 weeks
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
5378 trials
1
2
3
…50